We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Many lung cancers are driven by mutations in the epidermal growth factor receptor (EGFR), which occur in 10-15% of NSCLC patients in the US and the EU, and 30-40% of NSCLC patients in Asia.